Título:
|
Immunogenicity and immunization costs of adjuvanted versus
non-adjuvanted hepatitis B vaccine in chronic kidney disease
patients
|
Autor/a:
|
Vilajeliu, Alba; Sequera, Víctor Guillermo; García-Basteiro, Alberto L.; Sicuri, Elisa; Aldea, Marta; Velasco, César; Bayas Rodríguez, José María
|
Abstract:
|
Hepatitis B virus (HBV) vaccination is recommended for all
susceptible chronic pre-hemodialysis and hemodialysis patients.
This study assessed the immunogenicity of HBV vaccines
(adjuvanted and non-adjuvanted) in chronic kidney disease
patients vaccinated at the Hospital Clinic of Barcelona (Spain)
between January 2007 and July 2012. In addition, the costs for
the health system were evaluated according to the proportion of
vaccine responders after receiving either vaccine. Patients
receiving three doses of hepatitis B adjuvanted vaccine were
three times more likely to seroconvert than patients immunized
with non-adjuvanted vaccines, OR 3.56 (95% CI 1.84-6.85). This
resulted in fewer patients requiring a second course of HBV
vaccination and fewer outpatient visits, saving more than
euro9,500 per 100 patients. The higher immunogenicity of the
adjuvanted HBV vaccine would counterbalance the lower costs
associated with the non-adjuvanted vaccine. |
Materia(s):
|
-Hepatitis B -Malalties del ronyó -Hepatitis B -Kidney diseases |
Derechos:
|
(c) Taylor & Francis, 2016
|
Tipo de documento:
|
Artículo Artículo - Versión aceptada |
Editor:
|
Taylor & Francis
|
Compartir:
|
|